ImClone/Bristol Seek Priority Review For Erbitux Head And Neck Cancer Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Erbitux sBLA filing for head and neck cancer follows independent confirmatory review of Phase III trial.